Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.

Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, Comb MJ, Sourvinos G, Tsichlis PN.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):E613-21. doi: 10.1073/pnas.1115029109. Epub 2012 Feb 6.

2.

Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response.

Ezell SA, Tsichlis PN.

Transcription. 2012 Nov-Dec;3(6):305-9. doi: 10.4161/trns.21904. Epub 2012 Nov 1.

3.
4.

Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas.

Madjd Z, Akbari ME, Zarnani AH, Khayamzadeh M, Kalantari E, Mojtabavi N.

Asian Pac J Cancer Prev. 2014;15(4):1783-9.

5.

Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.

Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D, Eaves CJ.

J Natl Cancer Inst. 2005 Sep 7;97(17):1302-6.

PMID:
16145051
6.

The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.

Jelinic P, Eccles LA, Tseng J, Cybulska P, Wielgos M, Powell SN, Levine DA.

Oncotarget. 2017 Feb 21;8(8):13792-13804. doi: 10.18632/oncotarget.14637.

7.

EMSY promoted the growth and migration of ovarian cancer cells.

Zhao X, Zhou Y, Nie M, Xian S, Chen H, Wen Y, Zhang L, Huang Y, Chen M, Wang S.

Tumour Biol. 2015 Apr;36(4):3085-92. doi: 10.1007/s13277-014-2944-3. Epub 2014 Dec 16.

PMID:
25510665
8.

Expression of EMSY gene in sporadic ovarian cancer.

Altinisik J, Karateke A, Coksuer H, Ulutin T, Buyru N.

Mol Biol Rep. 2011 Jan;38(1):359-63. doi: 10.1007/s11033-010-0116-0. Epub 2010 Mar 28.

PMID:
20349280
9.

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T.

Cell. 2003 Nov 26;115(5):523-35.

10.

The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31.

Viré E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, Vidal A, Barbieri I, Aparicio S, Esteller M, Caldas C, Kouzarides T.

Mol Cell. 2014 Mar 6;53(5):806-18. doi: 10.1016/j.molcel.2014.01.029. Epub 2014 Feb 27. Erratum in: Mol Cell. 2014 Apr 10;54(1):203. Barbieri, Isaia [added].

11.

EMSY, a BRCA-2 partner in crime.

Livingston DM.

Nat Med. 2004 Feb;10(2):127-8. No abstract available.

PMID:
14760417
12.

Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.

Rodriguez C, Hughes-Davies L, Vallès H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C.

Clin Cancer Res. 2004 Sep 1;10(17):5785-91.

13.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
14.

Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131.

Varier RA, Carrillo de Santa Pau E, van der Groep P, Lindeboom RG, Matarese F, Mensinga A, Smits AH, Edupuganti RR, Baltissen MP, Jansen PW, Ter Hoeve N, van Weely DR, Poser I, van Diest PJ, Stunnenberg HG, Vermeulen M.

J Biol Chem. 2016 Apr 1;291(14):7313-24. doi: 10.1074/jbc.M115.701227. Epub 2016 Feb 3.

15.

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.

PMID:
21327470
16.

Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D.

Gynecol Oncol. 2006 Feb;100(2):264-70. Epub 2005 Oct 19.

PMID:
16236351
17.

Nuclear Akt2 opposes limbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway.

Saoncella S, Tassone B, Deklic E, Avolio F, Jon C, Tornillo G, De Luca E, Di Iorio E, Piva R, Cabodi S, Turco E, Pandolfi PP, Calautti E.

Stem Cells. 2014 Mar;32(3):754-69. doi: 10.1002/stem.1565.

18.

EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.

Navazio AS, Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L.

Breast Cancer Res Treat. 2016 Nov;160(1):181-186. Epub 2016 Sep 15.

PMID:
27628328
19.

Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.

Määttä KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, Laasanen SL, Schleutker J.

BMC Cancer. 2017 Jul 24;17(1):496. doi: 10.1186/s12885-017-3488-x.

20.

Overexpression and activation of Akt2 protein in oral squamous cell carcinoma.

Iamaroon A, Krisanaprakornkit S.

Oral Oncol. 2009 Oct;45(10):e175-9. doi: 10.1016/j.oraloncology.2009.06.003. Epub 2009 Jul 22.

PMID:
19628421

Supplemental Content

Support Center